Personalis (NASDAQ:PSNL) Trading 6.6% Higher – Here’s What Happened

Personalis, Inc. (NASDAQ:PSNL) shares traded up 6.6% on Friday . The stock traded as high as $6.92 and last traded at $7.0270. 284,518 shares were traded during mid-day trading, a decline of 80% from the average session volume of 1,393,591 shares. The stock had previously closed at $6.59.

Analysts Set New Price Targets

PSNL has been the topic of several recent research reports. BTIG Research upped their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Needham & Company LLC boosted their price target on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Morgan Stanley dropped their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Finally, Guggenheim raised their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Personalis has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Stock Up 2.0%

The stock has a market capitalization of $703.11 million, a P/E ratio of -7.38 and a beta of 2.02. The company has a 50-day moving average price of $8.81 and a two-hundred day moving average price of $8.22.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The company had revenue of $17.35 million during the quarter, compared to analyst estimates of $17.12 million. On average, sell-side analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

A number of institutional investors and hedge funds have recently made changes to their positions in PSNL. Caitong International Asset Management Co. Ltd grew its position in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Personalis during the second quarter worth about $30,000. International Assets Investment Management LLC bought a new position in shares of Personalis in the fourth quarter worth approximately $31,000. Ameritas Investment Partners Inc. bought a new position in shares of Personalis in the second quarter worth approximately $34,000. Finally, BNP Paribas Financial Markets raised its stake in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.